HEALTH.2012.1.4-1
HEALTH.2012.1.4-1
5 projects · €26,590,246 total EU contribution (project-level) · 58 participating organizations · 12 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€26,590,246
Countries active
Participant organizations by country (headquarters in CORDIS).
- France (14)
- Germany (11)
- Netherlands (8)
- UK (8)
- BE (4)
- Spain (4)
- SE (3)
- Italy (2)
- CH (1)
- CZ (1)
- EL (1)
- PT (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2 projects · FR
- IDIBAPS-CERCA2 projects · ES
- Institut klinické a experimentální mediciny2 projects · CZ
- KU Leuven2 projects · BE
- UOXF2 projects · UK
- Absorber1 projects · SE
- AMC1 projects · NL
- UNIVERSITAIR MEDISCH CENTRUM GRONINGEN1 projects · NL
- Leiden University Medical Center1 projects · NL
- acure1 projects · SE
- ALTA SRLU1 projects · IT
- AQIX1 projects · UK
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Consortium on Organ Preservation in Europe COPE · 305934 | FP7 | €5,990,843 | €7,847,753 | Details |
Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation BIO-DrIM · 305147 | FP7 | €5,989,000 | €7,978,285 | Details |
Biomarkers of renal graft injuries in kidney allograft recipients BIOMARGIN · 305499 | FP7 | €6,000,000 | €7,836,208 | Details |
A Europe-wide Strategy to enhance Transplantation of highly sensitized patients on basis of Acceptable HLA Mismatches EUROSTAM · 305385 | FP7 | €2,623,500 | €3,737,167 | Details |
Human monoclonal antibody therapy to prevent hepatitis C virus reinfection of liver transplants: advancing lead monoclonal antibodies into clinical trial HepaMAb · 305600 | FP7 | €5,986,903 | €7,825,523 | Details |